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ABSTRACT 
 
Galectin-9 is one of the key proteins employed by a variety of human malignancies to suppress anti-cancer 
activities of cytotoxic lymphoid cells and thus escape immune surveillance. Human cancer cells in most cases 
express higher levels of galectin-9 compared to non-transformed cells. However, the biochemical mechanisms 
underlying this phenomenon remain unclear.  
Here we report for the first time that in human cancer as well as embryonic cells, the transcription factors 
hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP-1) are involved in upregulation of transforming 
growth factor beta 1 (TGF-β1) expression, leading to activation of the transcription factor Smad3 through 
autocrine action. This process triggers upregulation of galectin-9 expression in both malignant (mainly in breast 
and colorectal cancer as well as acute myeloid leukaemia (AML)) and embryonic cells. The effect, however, was 
not observed in mature non-transformed human cells. TGF-β1-activated Smad3 therefore displays differential 
behaviour in human cancer and embryonic vs non-malignant cells. This study uncovered a self-supporting 
biochemical mechanism underlying high levels of galectin-9 expression operated by the human cancer and 
embryonic cells employed in our investigations. Our results suggest the possibility of using the TGF-β1 signalling 
pathway as a potential highly efficient target for cancer immunotherapy. 
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INTRODUCTION 
 
Galectin-9 is one of the crucial proteins used by various 
types of cancer cells to suppress cytotoxic immune 
responses and thus, escape immune surveillance [1]. 
Some cancer cells (acute myeloid leukaemia (AML) 
and colorectal cancer) are capable of secreting this 
protein, while other cancer cells translocate galectin-9 
onto the surface [1] and use it to impair anti-cancer 
activities of cytotoxic lymphoid cells such as cytotoxic 
T lymphocytes and natural killer (NK) cells [1–6]. 
Galectin-9 lacks a secretion signal sequence and thus 
cannot be secreted on its own. Its receptor, the T cell 
immunoglobulin and mucin domain containing protein 
3 (Tim-3), can also act as a possible trafficker for 
galectin-9 [7]. When complexed with Tim-3 on the cell 
surface, galectin-9 induces downstream signalling of 
differential intensity [8–10], depending on the type of 
human myeloid and lymphoid cells [11]. In myeloid 
cells, galectin-9 primarily triggers growth factor type 
responses, while in lymphoid cells it induces pro-
apoptotic signalling [10–13]. Galectin-9, together with 
Tim-3, can be shed from the cell surface by proteolytic 
enzymes, thus being released into the tumour 
microenvironment or blood [2].  
 
Human cancer cells express significantly higher levels 
of galectin-9 compared to healthy human cells [1]. In 
particular, high amounts of galectin-9 are secreted by 
AML and colorectal cancer cells [1, 14]. However, the 
biochemical mechanisms underlying increased galectin-
9 expression in human cancer cells are unknown. 
Understanding these mechanisms will significantly 
improve our knowledge concerning the biochemistry of 
malignant tumour immune escape and would facilitate 
identification of new targets for efficient cancer 
immunotherapy. 
 
It has been reported that human cancer cells produce 
transforming growth factor beta type 1 (TGF-β1, also 
known as TGF-β), that can display autocrine activity by 
binding to TGF-β receptors (TGFBR) [15, 16]. TGF-β 
is known to transduce its signal via the Smad3 
transcription factor, which triggers the expression of 
target genes [17]. The galectin-9 gene LGALS9 
promoter region has several (at least 5) Smad3 response 
elements and Smad3 has been reported to induce 
galectin-9 expression [18, 19]. In addition, the TGF-β 
encoding gene has at least 9 Smad3 response elements 
in its promoter region and thus could also upregulate 
TGF-β expression in an autocrine manner capable of 
supporting itself without external signals. Initial 
activation of TGF-β could be induced by the hypoxia-
inducible factor 1 (HIF-1) transcription complex, which 
contains two subunits – a constitutive β subunit and an 
inducible α subunit. HIF-1 displays high activity in the 
early stages of tumour growth and thus could initiate 
TGF-β expression [20], which can then trigger the 
autocrine pathway described above leading to galectin-9 
overexpression. In addition, the activities of enzymes 
which generate reactive oxygen species (ROS), such as 
NADPH oxidase and xanthine oxidase, are elevated in 
cancer cells compared to healthy cells in corresponding 
tissues [20, 21]. Increased ROS levels lead to the 
activation of apoptosis signal regulating kinase 1 
(ASK1) and its downstream pathway, resulting in 
activation of the AP-1 (activator protein 1) [22] 
transcription complex which could upregulate TGF-β 
expression.  
 
Importantly, similar events could also occur in human 
embryonic cells, thus leading to the expression of high 
levels of galectin-9 and preventing embryo rejection by 
mother’s immune system [23]. Experimental 
investigation of this complex hypothesis became the 
aim of this study.  
 
Here we report for the first time that in human breast 
cancer, AML and embryonic cells, HIF-1 and AP-1 
upregulate the expression of TGF-β, leading to the 
activation of Smad3 through autocrine action. This 
process subsequently upregulates galectin-9 expression 
in both malignant and embryonic cells, but not in 
mature healthy human cells. Activated Smad3 therefore 
displays differential behaviour in cancer/embryonic vs 
healthy cells.  
 
RESULTS 
 
HIF-1, TGF-β, Smad3 and galectin-9 are highly 
upregulated in primary human cancer and 
embryonic cells 
 
In order to investigate the hypothesis of self-sustaining 
upregulation of TGF-β and galectin-9 expression in 
human cancer and embryonic cells we tested primary 
human breast tumours, primary AML cells as well as 
primary embryonic cells.  
 
We found that all five tested breast cancer patients 
showed very high levels of xanthine oxidase and 
NADPH oxidase activities as well as thiobarbiturate-
reactive species (TBRS, products of lipid peroxidation 
indicating increased oxidative burst) levels in tumour 
tissues compared to healthy tissues (Figure 1A, 1B). 
Respectively, levels of HIF-1α were also significantly 
higher in tumour samples (Figure 1C). This was in 
line with the highly increased amounts of tumour-
associated TGF-β and intracellular levels of phospho-
S423/S425-Smad3 (active form, Figure 1C). In line 
with our previous observations [1], levels of both 
Tim-3 and galectin-9 were substantially increased in  
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tumour tissues compared to non-malignant samples 
(Figure 1D). 
 
Similar observations were seen in AML, a non-solid 
malignancy. AML cells isolated from newly diagnosed 
patients were compared with primary leukocytes 
isolated from healthy donors upon culturing them for 24 
h. AML cells showed significantly upregulated xanthine 
oxidase and NADPH oxidase activities as well as TBRS 
levels (Figure 2A), which suggests a higher level of 
oxidative stress in AML cells. HIF-1α and phospho-
S423/S425-Smad3 were almost undetectable in primary 
healthy leukocytes, but were clearly detectable in AML 
cells (Figure 2B). AML cells released significantly 
higher amounts of TGF-β compared to healthy 
leukocytes. Respectively, AML cells secreted much 
higher amounts of both Tim-3 and galectin-9 (Figure 
2C; secreted levels were measured since over 24 h 
AML cells release much higher amounts of these 
proteins compared to those present in the cells at a 
single moment of time, when the cells are harvested).  
 
To understand the role of TGF-β we analysed blood 
plasma of six healthy donors, six primary breast cancer 
patients, six metastatic breast cancer patients and six 
AML patients. In cases of primary and metastatic breast 
cancers, blood plasma levels of TGF-β were similar to 
those in healthy donors. However, in AML patients they 
were strikingly and significantly elevated (Figure 3). 
These results suggest that in solid tumours, like primary 
and metastatic breast tumours, produced TGF-β most 
likely remains in the tumour microenvironment while in 
the case of AML, this growth factor is secreted into the 
peripheral blood and can be employed by circulating 
AML cells.  
 
Intriguingly, primary human embryonic cells obtained 
from chorion (around week 13 of pregnancy) of seven 
pregnant patients and amniotic liquid obtained from 
another seven patients (between weeks 20 and 25) had 
clearly detectable activities of xanthine oxidase, 
NADPH oxidase and TBRS (Figure 4A). The earlier the 
stage was, the higher was the level of oxidative burst. A
 
Figure 1. Increased redox status, upregulated HIF-1α and TGF-β/Smad3 pathways as well as Tim-3 and galectin-9 
expression in breast tumour tissues compared to non-transformed peripheral tissues. The proposed pathway studied is 
summarised in panel (A), where it is indicated that xanthine oxidase (XOD) and NADPH oxidase (Nox) produce ROS which activate AP -1 
transcription factor through ASK1-controlled MAP kinase cascades. HIF-1 and AP-1 contribute to the activation of TGF-β expression, 
which then displays autocrine activity and stimulates the activation of galectin-9 and possibly Tim-3 expression through Smad3 
transcription factor. Tissue lysates were subjected to measurement of xanthine oxidase and NADPH oxidase activities as well a s TBRS 
levels (B). HIF-1α accumulation, tissue-associated TGF-β and phospho-S423/S425-Smad3 levels (C) as well as levels of tissue-
associated Tim-3 and galectin-9 (D) were analysed in tissue lysates. All quantities are expressed in respective units per 1 gram of the 
tissue. Normalisations against total protein loaded (for Western blot; measured by Li-Cor protein assay kit) and per mg of the total 
protein for enzyme activities and TBRS assays were also performed. These results are presented in the Supplementary Figure 1. 
Images are from one experiment representative of five which gave similar results. Data are shown as mean values ± SEM of five 
independent experiments. * - p < 0.05 and ** - p < 0.01 vs non-transformed peripheral tissue abbreviated as HT (healthy tissue).  
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Figure 2. Increased redox status, upregulated HIF-1α and TGF-β/Smad3 pathways as well as Tim-3 and galectin-9 expression 
in primary human AML cells compared to non-transformed mononuclear leukocytes. Measurements were conducted in primary 
human AML cells vs primary mononuclear leukocytes obtained from healthy donors. Activities of xanthine oxidase, NADPH oxidase and TBRS 
levels (A). Levels of accumulated HIF-1α protein and phospho-S423/S425-Smad3 (B). Levels of secreted TGF-β, Tim-3 and galectin-9 measured 
in cell culture medium (C). Images are from one experiment representative of five which gave similar results. Data are shown as mean values 
± SEM of five independent experiments. * - p < 0.05 and ** - p < 0.01 vs non-transformed (“healthy”) primary human mononuclear 
leukocytes (abbreviated as PHL – “primary healthy leukocytes”).  
 
 
Figure 3. Levels of secreted TGF-β in blood plasma of healthy donors, primary and metastatic breast cancer patients and 
AML patients. TGF-β concentrations were measured in blood plasma of healthy donors, patients with primary breast tumours, patients 
with metastatic breast solid tumours and AML patients (n=6 for all donor types). Data are shown as mean values ± SEM (data for each patient 
are shown). * - p < 0.05 vs healthy donors.  
 
www.aging-us.com 23482 AGING 
similar pattern was observed for HIF-1α, secreted TGF-
β and phospho-S423/S425-Smad3 levels (Figure 4B, 
4C). Respectively, Tim-3 and galectin-9 were clearly 
detectable in both cell types, although not secreted, and 
were significantly higher at earlier pregnancy stages 
(Figure 4D, 4E).  
 
Redox-dependent mechanisms contribute to TGF-β 
and galectin-9 expression 
 
In order to understand the ability of redox-dependent 
ASK1-mediated activation of AP-1 in TGF-β and 
galectin-9 production, we used THP-1 human acute 
myeloid leukaemia cells which express Toll-like 
receptor 4 (TLR4; Figure 5A). Cells were exposed for 
24 h to 1 µg/ml high mobility group box 1 (HMGB1) 
protein. We found that HMGB1 induced the secretion 
of TGF-β and galectin-9 by THP-1 cells (Figure 5B). To 
investigate the contribution of the NADPH oxidase–
ASK1–AP-1 redox-dependent pathway to TGF-β 
expression we pre-treated the cells with 30 µM DPI 
(Diphenyleneiodonium chloride, NADPH oxidase 
inhibitor) or 1 µM SR11302 (AP-1 inhibitor) for 1 h 
before exposing them for 24 h to HMGB1. Another set 
of cells was subjected to transfection with dominant-
negative ASK1 (ΔN-ASK1), to block the activity of this 
enzyme prior to the 24 h exposure to HMGB1. We 
found that HMGB1 induced TGF-β and galectin-9 
secretion (Figure 5B). DPI, SR11302 and ΔN-ASK1 
attenuated the effect, suggesting that redox-induced 
ASK-1-mediated AP-1 activation leads to increased 
TGF-β and galectin-9 production by THP-1 cells.  
 
We then studied the ability of xanthine oxidase to 
upregulate TGF-β production. We used MCF-7 breast 
cancer cells, which express xanthine oxidase [21] and 
induced its activity by ammonium molybdate. Xanthine 
oxidase is a molybdenum-containing enzyme, so excess 
of molybdenum converts all the available xanthine 
oxidase molecules into their active form. To confirm the 
specificity of the effect we exposed MCF-7 cells to 100 
µg/ml ammonium molybdate for 24 h in the absence or 
presence of 250 µg/ml allopurinol, a specific xanthine 
oxidase inhibitor. We found that xanthine oxidase 
activity was significantly upregulated by molybdate in 
MCF-7 cells (Figure 6A). This led to increased 
oxidative burst based on significantly increased TBRS 
levels. Xanthine oxidase activation was not able to 
induce HIF-1α accumulation but the level of secreted 
TGF-β was significantly increased (Figure 6A). This 
resulted in a significant upregulation of Smad3 
S423/S425 phosphorylation (Figure 6B). As a result, 
galectin-9 expression was also significantly increased 
(Figure 6B). Allopurinol attenuated all these effects 
(Figure 6A, B), indicating a specific role for xanthine 
oxidase in the processes outlined above.  
The HIF-1 transcription complex triggers galectin-9 
expression by inducing TGF-β production; Smad3 is 
involved in both TGF-β and galectin-9 expression 
 
We then considered the effect of HIF-1 activation on 
TGF-β production and its subsequent effect on galectin-
9 expression. We exposed wild type and HIF-1α 
knockdown (achieved by transfection of HIF-1α 
siRNA) MCF-7 cells as well as those transfected with 
random siRNA to 50 µM cobalt chloride (CoCl2) for 6 h 
(Co cations directly inhibit degradative hydroxylation of 
HIF-1α [24]), followed by measurement of HIF-1 
DNA-binding activity, cell-associated and secreted 
TGFβ (ELISA) as well as cellular galectin-9 levels 
(Western blot – MCF-7 cells do not secrete galectin-9). 
We found that CoCl2 induced significant upregulation 
of HIF-1 DNA-binding activity in wild type and random 
siRNA-transfected MCF-7 cells (Figure 7A). No effect 
was observed in HIF-1α knockdown cells (Figure 7A). 
In wild type cells CoCl2 induced significant 
upregulation of secreted and total levels of TGF-β. The 
effect was not observed in HIF-1α knockdown cells 
(Figure 7A). In MCF-7 cells transfected with random 
siRNA, the level of total TGF-β was upregulated to the 
one observed in wild type cells exposed to CoCl2. 
However, the application of DOTAP to transfect these 
cells with random siRNA together with CoCl2 slowed 
down the process of TGF-β secretion. As a result, the 
level of galectin-9 was only upregulated in wild type 
MCF-7 cells treated with CoCl2 (Figure 7). These 
results suggest that HIF-1 induces the expression of 
TGF-β, which then facilitates the upregulation of 
galectin-9 expression. To further investigate this 
assumption we studied the dynamics of the process. We 
exposed wild type MCF-7 cells to 50 µM CoCl2 for 1, 
2, 3, 4, 5 and 6 h time points and detected HIF-1 DNA-
binding activity, levels of secreted TGF-β and cellular 
galectin-9 expressions. We found that HIF-1 DNA-
binding activity was increased after 1 h of exposure to 
CoCl2, while the levels of secreted TGF-β were 
significantly increased following 3 h of exposure 
(Figure 7B). Cellular galectin-9 level was significantly 
upregulated only in 6 h of exposure to CoCl2 (Figure 
7B). To specifically confirm the contribution of TGF-β 
in regulating galectin-9 expressions, we exposed wild 
type MCF-7 cells to 50 µM CoCl2 for 6 h in the absence 
or presence of TGF-β neutralising antibody or isotype 
control antibody. We found that TGF-β neutralising 
antibody but not the isotype control attenuated CoCl2-
induced galectin-9 upregulation in MCF-7 cells (Figure 
7C). All these findings clearly demonstrated that HIF-1 
induces TGF-β production which displays autocrine 
activity and triggers galectin-9 expression.  
 
In order to confirm the role of Smad3 in both TGF-β 
and galectin-9 expression we used wild type and Smad3
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Figure 4. Oxidative burst, HIF-1α accumulation, TGF-β/Smad3 pathway and Tim-3/galectin-9 levels are highly upregulated in 
primary human embryonic cells at early pregnancy stages. Primary human embryonic cells, obtained from amniotic fluid (Am, around 20 - 
25 weeks of pregnancy) and chorion (Ch, around 13 weeks of pregnancy), were subjected to measurement of xanthine oxidase and NADPH oxidase 
activities as well as TBRS levels (A). HIF-1α accumulation (B), secreted TGF-β and cell-associated phospho-S423/S425-Smad3 levels were also 
analysed (C), as well as levels of cell-associated and secreted Tim-3 (D) and galectin-9 (E). Images are from one experiment representative of seven, 
which gave similar results. Data are shown as mean values ± SEM of seven independent experiments. * - p < 0.05 vs amniotic cells.  
 
 
Figure 5. Oxidative stress-induced activation of AP-1 in an ASK1-dependent manner induces TGF-β and galectin-9 expression. THP-
1 cells were treated with the Toll-like receptor 4 (TLR4) ligand, high mobility group box 1 (HMGB1), for 24 h. TLR4 mediates activation of NADPH 
oxidase using myeloid differentiation factor 88 (MyD88), TLR4 TIR domain-associated protein (TIRAP) and Bruton’s tyrosine kinase (Btk). Activation 
of Btk by MyD88 and TIRAP leads to Btk-dependent phosphorylation of phospholipase C (PLC, mainly isoform 1γ), which triggers activation of 
protein kinase C alpha (PKCα). PKCα activates NADPH oxidase which produces superoxide anion radical, activating the ASK1 pathway and activation 
of AP-1 transcription factor. The scheme is shown in panel (A). THP-1 cells were exposed for 24 h to 1 µg/ml HMGB1 with or without pre-treatment 
with 30 µM DPI (NADPH oxidase inhibitor), 1 µM SR11302 (AP-1 inhibitor) or transfection with dominant-negative isoform of ASK1 (ΔN-ASK1). 
Levels of secreted TGF-β and galectin-9 were measured by ELISA (B). Data are shown as mean values ± SEM of four independent experiments. * - p 
< 0.05 and ** - p < 0.01 vs control. 
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Figure 6. Xanthine oxidase activation leads to increased oxidative stress and upregulation of the TGF-β/Smad3 pathway as 
well as galectin-9 expression. MCF-7 human breast cancer cells were exposed to ammonium molybdate for 24 h to induce xanthine 
oxidase activity in the absence or presence of the xanthine oxidase inhibitor allopurinol. Xanthine oxidase activity, TBRS levels, HIF-1α 
accumulation, secreted TGF-β (A), and cell-associated phospho-S423/S425-Smad3, Tim-3 and galectin-9 (B) were analysed as outlined in the 
Materials and Methods. Images are from one experiment representative of four which gave similar results. Data are shown as mean values ± 
SEM of four independent experiments. * - p < 0.05 and ** - p < 0.01 vs indicated events. 
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knockdown MCF-7 cells. As a control for reagents, we 
used MCF-7 cells transfected with random siRNA as 
outlined in Materials and Methods. Cells were exposed 
to 2 ng/ml TGF-β for 24 h and cell-associated (in cell 
lysates) and the levels of secreted (in cell culture 
medium) TGF-β were measured by ELISA. Phospho-
S423/S425-Smad3 and galectin-9 were measured in cell 
lysates to confirm successful knockdown and to assess 
the effects on galectin-9 expression (Figure 7D). We 
found that the presence of TGF-β led to an increase in 
secreted TGF-β levels (Figure 7E). This increase did not 
take place in Smad3 knockdown cells. The same was 
applicable to the levels of galectin-9 (Figure 7E). MCF-
7 cells transfected with random siRNA displayed 
increased levels of cell-associated as well as secreted 
TGF-β. This resulted in upregulation of galectin-9 
expression as well (Figure 7E). However, MCF-7 cells 
transfected with random siRNA in the presence of 
CoCl2 displayed higher levels of cell-associated TGF-β 
and lower levels of secreted protein compared to similar 
cells treated with TGF-β. This means that the presence 
of DOTAP reagent and cobalt cations reduces the 
ability of MCF-7 cells to secrete de novo produced 
TGF-β.  
 
TGF-β induces galectin-9 expression in human 
cancer and embryonic cells 
 
To confirm and study the differential effects of TGF-β 
on galectin-9 expression we treated THP-1 human AML 
cells, Colo205 human colorectal cancer cells, MCF-7 
human breast cancer cells, HaCaT human keratinocytes 
(non-malignant cells), primary healthy human 
keratinocytes as well as HEK293 human embryonic 
kidney cells, with 2 ng/ml human recombinant TGF-β 
(specifically TGF-β type 1 was used) for 24 h. Cellular 
and secreted levels of galectin-9 and Tim-3 were then 
determined. We found that in all types of human cancer 
cells and in HEK293, TGF-β upregulated the amounts 
of expressed galectin-9 but not Tim-3. However, in non-
malignant cells (both types of keratinocytes), no 
upregulation of either galectin-9 or Tim-3 expression 
was observed (Figure 8). Both types of keratinocytes 
expressed barely detectable levels of galectin-9 and this 
was not inducible by TGF-β. To find out whether such a 
phenomenon (the absence of induction of galectin-9 
expression by TGF-β) applies also to cancer cells we 
used K562 chronic myeloid leukaemia cells which 
express only traces of galectin-9 protein [1] compared 
to for example THP-1 or other AML cells. Exposure of 
these cells to increasing concentrations of TGF-β for 24 
h led to a clear induction of galectin-9 expression 
(Supplementary Figure 2), suggesting differential 
responses of cancer/embryonic and non-malignant 
mature human cells. Importantly, levels of phospho-
S423/S425 Smad-3 were undetectable in resting K562 
cells and were clearly detectable in TGF-β-treated cells 
(Supplementary Figure 2). Regardless the treatment, 
K562 cells did not release detectable amounts of 
galectin-9 (Supplementary Figure 2).  
 
Since Smad3 is the transcription factor activated by 
TGF-β, which then induces galectin-9 expression, we 
compared TGF-β-induced S423/S425 Smad3 
phosphorylation in malignant and non-malignant human 
cells. MCF-7 breast cancer cells as well as non-
malignant HaCaT cells and primary keratinocytes were 
exposed for 24 h to 2 ng/ml TGF-β followed by 
measurement of phospho-S423/S425 Smad3. We 
detected significant upregulation of phospho-
S423/S425-Smad3 levels only in MCF-7 cells but not in 
non-malignant keratinocytes. In addition, the profile of 
the phospho-S423/S425-Smad3 band was different in 
malignant and non-malignant cells (Figure 9). Taken 
together these results suggest that TGF-β-induced 
Smad3-mediated galectin-9 expression takes place 
mainly in human cancerous and embryonic cells. The 
responses associated with TGF-β-induced S423/S425 
Smad3 phosphorylation are clearly different in 
cancer/embryonic and mature non-malignant human 
cells.  
 
DISCUSSION 
 
Galectin-9 plays a crucial role in determining the ability 
of cancer cells to escape host immune surveillance [1, 
2]. As with all galectins, galectin-9 lacks a secretion 
signal sequence and thus requires trafficking in order to 
be externalised onto the cell surface or secreted [1, 7]. 
Cell surface-based or secreted galectin-9 can impair 
anti-cancer activities of NK and cytotoxic T cells [1, 2, 
6, 7]. Tim-3 acts as a receptor and possible trafficker for 
galectin-9 and also participates in the transduction of 
moderate growth signals from galectin-9 into cancer 
cells (for example AML cells) as well as pro-apoptotic 
signals into cytotoxic T cells [3].  
 
Many types of cancer cells express significantly higher 
amounts of galectin-9 compared to non-malignant cells 
of similar origin [1]. However, the biochemical 
mechanisms underlying this phenomenon remain 
unclear and thus investigation of galecin-9 expression 
control pathways was the main goal of this study.  
 
We hypothesised that TGF-β, a growth factor with 
autocrine activity, is responsible for the upregulation of 
galectin-9 expression in cancer cells. We found that 
human breast tumour cells and AML cells produced 
significantly higher levels of TGF-β compared to non-
transformed cells of similar origin. Interestingly, the 
levels of oxidative stress and activities of ROS 
producing enzymes (xanthine oxidase and NADPH  
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oxidase) were significantly higher in cancer 
cells/tissues. Oxidative stress normally leads to 
activation of the AP-1 transcription complex [22], 
which contributes to TGF-β expression [25]. In 
addition, the levels of HIF-1α accumulation were much 
higher in cancer samples. HIF-1α determines 
transcriptional activity of the HIF-1 complex, which 
directly activates the expression of TGF-β. As a result 
of increased TGF-β activity, the levels of 
phosphorylated (active, when phosphorylated at 
S423/S425) Smad3, which is a TGF-β transcription 
factor, were significantly upregulated in the studied 
cancer cells/tissues. The levels of galectin-9 and its 
receptor Tim-3 were upregulated in all the studied 
cancer cell types (these results are shown in Figures 1 
and 2). Interestingly, AML but not breast cancer 
patients showed significantly increased blood plasma 
levels of TGF-β (Figure 3), which suggests that in 
breast (solid) tumours TGF-β remains within tumour 
microenvironment, while in AML it is secreted into the 
blood thus having the opportunity to systemically act on 
AML cells in circulation.  
 
Importantly, primary human embryonic cells showed 
the same pattern as breast cancer and AML cells (Figure 
4). The earlier the stage the pregnancy was, the higher 
were the levels of galectin-9 and Tim-3 and components 
of the possible upstream pathway outlined above. 
Embryonic cells were similar to breast and other solid 
tumour cells and not like AML cells in terms of 
galectin-9 and Tim-3 secretion and where unable to 
secrete detectable amounts of these proteins (Figure 4).  
 
 
Figure 7. HIF-1 and Smad3 are involved in the production of TGF-β and galectin-9. (A) Cobalt chloride induces HIF-1 activation, TGF-β and 
galectin-9 production. Wild type, HIF-1α knockdown and random siRNA-transfected MCF-7 cells were exposed to 50 µM cobalt chloride for 6 h 
followed by measurement of HIF-1 DBA, secreted (in cell culture medium) and cell-associated (in cell lysates) TGF-β as well as cell-associated 
galectin-9. Images are from one experiment representative of three which gave similar results. (B) Dynamics of cobalt chloride-induced HIF-1 
activation, TGF-β and galectin-9 accumulation in MCF-7 human breast cancer cells. MCF-7 cells were exposed to 50 µM cobalt chloride for 1, 2, 3, 4, 
5 and 6 h followed by measurement of HIF-1 DBA, secreted and cell-associated TGF-β as well as cell-associated galectin-9. Images are from one 
experiment representative of three which gave similar results (in the case of TGF-β – vs 1 h time-point since at zero point cells can’t release any 
TGF-β. At this time-point, fresh medium has just been supplied and measurement was taken immediately to confirm zero TGF-β level). (C) HIF-1-
induced galectin-9 expression is mediated by TGF-β. MCF-7 cells were exposed to 50 µM cobalt chloride for 6 h with or without presence of TGF-β 
neutralising or isotype control antibody. Galectin-9 expression was then assessed by Western blot. Images are from one experiment representative 
of three, which gave similar results. (D), (E) Smad3 is involved in TGF-β and galectin-9 expression. (D) Scheme of the experiment performed showing 
studied effects. (E) Wild type, Smad3 knockdown and random siRNA-transfected MCF-7 cells were exposed to 2 ng/ml TGF-β for 24 h followed by 
measurement of secreted (in cell culture medium) and cell-associated (in cell lysates) TGF-β as well as cell-associated galectin-9 and phospho-
S423/S425 Smad3. Images are from one experiment representative of three, which gave similar results. All quantitative data are shown as mean 
values ± SEM (n=3-4) * - p < 0.05 and ** - p < 0.01 vs indicated events. 
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We have confirmed that upregulation of both 
NADPH oxidase and xanthine oxidase are capable of 
increasing TGF-β production. HMGB1-induced 
NADPH oxidase activation led to upregulated TGF-β 
and galectin-9 production by THP-1 human AML 
cells. Blockade of NADPH oxidase activity, ASK1 
kinase activity or AP-1 transcriptional activity 
decreased HMGB1-induced effects (Figure 5). 
Importantly, from our previous work we know  
that HMGB1 acts through Toll-like receptors (TLRs) 
2 and 4 causing oxidative stress and also inducing 
HIF-1 activation [26]. AP-1 is known to  
be required for TGF-β expression although it  
 might not directly act on the TGF-β gene [25],
 
 
Figure 8. TGF-β induces galectin-9 expression in human cancer and embryonic but not healthy cells. THP-1 (AML), Colo-205 
(colorectal cancer), MCF-7 (breast cancer) HaCaT (keratinocytes), primary human keratinocytes (Prim KC) as well as HEK293 (human 
embryonic kidney cells) were exposed for 24 to 2 ng/ml human recombinant TGF-β. Levels of cell-associated Tim-3 and galectin-9 as well as 
secreted galectin-9 were measured. Images are from one experiment representative of four which gave similar results. Data are shown as 
mean values ± SEM of four independent experiments.* - p < 0.05 vs control.  
 
 
Figure 9. The effects of TGF-β on Smad3 phosphorylation in human cancer and non-malignant cells. (A) MCF-7 (breast cancer), 
(B) HaCaT (keratinocytes) and (C) primary human keratinocytes were exposed for 24 h to 2 ng/ml TGF-β followed by Western blot analysis of 
phospho-S423/S425-Smad3 levels. Images are from one experiment representative of four which gave similar results. Data are shown as 
mean values ± SEM of four independent experiments. * - p < 0.05 vs control. 
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However, blocking AP-1 attenuates any HMGB1-
induced increase in TGF-β and subsequent galectin-9 
production. Specific activation of xanthine oxidase in 
MCF-7 human breast cancer cells also upregulated the 
level of oxidative burst, however it was not sufficient to 
induce HIF-1α accumulation (Figure 6A). Despite this, 
TGF-β/phospho-S423/425-Smad3 and galectin-9 levels 
were significantly upregulated suggesting contribution 
of the AP-1 pathway (Figure 6B).  
 
We also confirmed the role of HIF-1 in TGF-β 
expression by exposing MCF-7 breast cancer cells to 
CoCl2, which inhibits degradative hydroxylation of 
HIF-1α thus causing its stabilisation, leading to HIF-1 
activation. Importantly, CoCl2 is known to induce 
oxidative stress by increasing ROS generation which is 
achieved through acting on the mitochondrial transition 
pore [27, 28]. As a result, it leads to formation of free 
oxygen containing radicals which trigger ASK1-
mediated AP-1 activation [22]. These experiments 
demonstrated the importance of HIF-1 in regulating 
TGF-β expression. While AP-1 is required but does not 
seem to control TGF-β gene expression directly, HIF-1 
acts as a direct regulator. We found that CoCl2 induced 
TGF-β and galectin-9 expression in wild type but not in 
HIF-1α knockdown MCF-7 cells. This confirms the 
involvement of HIF-1 in CoCl2-induced TGF-β 
expression. Interestingly, in MCF-7 cells transfected 
with random siRNA, TGF-β expression was 
upregulated, although DOTAP transfection and the 
presence of CoCl2, but not TGF-β, slowed down the 
secretion process and galectin-9 expression was not 
increased, suggesting that it might depend on the 
autocrine activity of secreted TGF-β (Figure 7A). When 
studying the process in dynamics we found that CoCl2 
rapidly induces HIF-1 activation in MCF-7 cells (after 1 
h of exposure, a significant increase in HIF-1 DNA-
binding activity was clearly detectable, Figure 7B). 
Secreted TGF-β levels were significantly increased after 
3-4 h of cell exposure to CoCl2 whereas galectin-9 
levels were only significantly upregulated after 6 h. 
This supports the notion that CoCl2-induced galectin-9 
expression depends on the autocrine activity of TGF-β, 
the expression of which is induced by the HIF-1 
transcription complex. We specifically confirmed the 
role of HIF-1-induced TGF-β production in 
upregulating the expression of galectin-9 in MCF-7 
cells. Wild type MCF-7 cells were exposed to 50 µM 
CoCl2 in the absence or presence of TGF-β-neutralising 
antibody or isotype control antibody (Figure 7C). Since 
TGF-β-neutralising antibody but not isotype control 
attenuated CoCl2-induced galectin-9 expression, it 
demonstrates that the autocrine activity of this growth 
factor crucially controls the expression of galectin-9. 
The whole pathway includes activation of HIF-1 which 
upregulates TGF-β expression; TGF-β is then secreted 
and displays autocrine activity leading to the induction 
of galectin-9 expression in MCF-7 breast cancer cells. 
The role of Smad3 in both TGF-β self-induced 
expression and production of galectin-9 was confirmed 
using Smad3 knockdown MCF-7 cells.  
 
Our study further demonstrated that TGF-β induces 
galectin-9 expression in human AML, breast and 
colorectal cancer as well as embryonic cells but not in 
the studied healthy (non-malignant) human cells. 
Importantly, in healthy human cells (keratinocytes) 
expressing barely detectable amounts of galectin-9, 
TGF-β cannot induce galectin-9 expression, while if 
cancer cells (for example K562 chronic myeloid 
leukaemia cells) express only traces of galectin-9, 
TGF-β can induce expression of this protein (Figure 8 
and Supplementary Figure 2). This is in line with 
previous observations suggesting differential Smad3-
dependent TGF-β signalling effects in malignant and 
non-malignant cells [17, 29]. Our investigations 
further confirmed that TGF-β induces S423/S425-
phosphorylation of Smad3 in the studied cancer cells 
but not in healthy human cells. In addition, phospho-
S423/S425-Smad3 Western blot band profiles vary 
between malignant and non-malignant human cells 
(Figure 9). This suggests differential responses of the 
investigated malignant/embryonic and non-malignant 
mature human cells to TGF-β in terms of their ability 
to react by significantly increasing galectin-9 
expression. One could hypothesise that another reason 
for these differences in responses could be in 
differential reactivity of the cells in terms of TGFBR 
expression or their downstream signalling. 
Cancer/embryonic cells may retain high levels of 
TGFBRs on their surface while non-transformed cells 
may decrease these levels in response to the presence 
of high levels of TGF-β in the microenvironment. 
Another possibility is the involvement of differential 
co-activator proteins recruited by Smad3 in different 
cell types [30]. There are two main co-activators of 
Smad3 – transcription intermediary factor 1-gamma 
(TIF-1γ) also known as TRIM33 (tripartite motif-
containing factor 33) and Smad4 [30]. Both co-
activators and also some other binding partners (for 
example Smad2) are known to interact with Smad3 
which influences the response Smad3 is going to 
trigger. In future work it will be important to 
understand which of co-activators/chaperons are 
involved in galectin-9 expression in different cell 
types.  
 
Interestingly, in support of our observations, a  
previous clinical study has demonstrated that high 
expression levels of TGF-β receptors (TGFBRs) are 
associated with poor prognosis for AML patients and 
have a significant negative impact on complete 
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remission achievement and long-term survival of these 
patients [31].  
 
Our observations suggest, that during early stages of 
tumour growth or embryonic development, when the 
cells pass through a low oxygen availability stage, 
activation of HIF-1 induces TGF-β expression. TGF-β 
can then display autocrine activity and induce galectin-9 
expression (a summary is shown in Figure 10). At later 
stages, when angiogenesis addresses the issue of low 
oxygen availability and normalises it, TGF-β can induce 
its own expression through the Smad3 transcription 
factor. At the same time, Smad3 can induce the 
expression of galectin-9 (see Figure 10). Therefore, 
cancer and embryonic cells studied here operate a self-
supporting autocrine mechanism which is a two-stage 
process. During the early stage, initial TGF-β 
expression is, most likely, induced by the HIF-1 
transcription complex and at later stages, TGF-β 
triggers self-expression. At both stages, TGF-β induces 
galectin-9 expression through the Smad3 pathway. 
Interestingly, TGF-β can display both tumour 
promoting and tumour suppressing biochemical 
activities [29]. However, tumour suppressive activities 
of the TGF-β are often avoided by tumours through 
acquiring mutations in critical signalling proteins or by 
just inhibiting TGF-β-induced anti-proliferative 
responses [29]. 
 
These finding demonstrate a self-supporting mechanism 
of galectin-9 expression operated by human AML, 
breast and colorectal cancer as well as embryonic cells.
 
 
Figure 10. Proposed mechanism of the regulation of galectin-9 expression in human cancer and embryonic stage at low and 
normal oxygen availability stages. The figure depicts the key processes taking place in embryonic development and malignant tumour 
growth during the initial low oxygen availability (hypoxic) stage and later (normal oxygen availability) stages. The studied biochemical events 
are demonstrated in the right-hand panel. During the hypoxic stage, HIF-1 induces TGF-β expression, which then displays autocrine activity 
and triggers galectin-9 expression in a Smad3-dependent manner. During the normal oxygen availability stage, AP-1 contributes to TGF-β 
expression but it is also self-triggered by TGF-β. Galectin-9 upregulation is perpetually induced by the TGF-β-Smad3 pathway.  
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Our results suggest the possibility of using TGF-β 
signalling as a potential highly efficient target for 
cancer immunotherapy.  
 
MATERIALS AND METHODS 
 
Materials 
 
RPMI-1640 cell culture medium, foetal bovine serum 
and supplements as well as basic laboratory chemicals 
were purchased from Sigma (Suffolk, UK). Microtitre 
plates for ELISA were obtained from Oxley Hughes Ltd 
(London, UK). Rabbit antibodies against galectin-9 and 
phospho-S423/S425-Smad3 as well as mouse antibody 
against HIF-1α were purchased from Abcam 
(Cambridge, UK). Antibodies against β-actin were 
purchased from Abcam (Cambridge, UK) and 
Proteintech (Manchester, UK). Goat anti-mouse and 
anti-rabbit fluorescently--labelled dye secondary 
antibodies were obtained from Li-COR (Lincoln, 
Nebraska USA). ELISA-based assay kits for the 
detection of galectin-9, Tim-3 and TGF-β as well as 
human recombinant TGF-β1 protein were purchased 
from Bio-Techne (R&D Systems, Abingdon, UK). 
Anti-Tim-3 mouse monoclonal antibody was described 
before [8]. All other chemicals purchased were of the 
highest grade of purity commercially available. 
 
Cell lines and primary human samples 
 
Cell lines used in this work were purchased from either 
the European Collection of Cell Cultures (THP-1, Colo-
205 and MCF-7), the American Tissue Culture 
Collection (ATTC, - HEK293) or CLS Cell Lines 
Service GmbH (HaCaT keratinocytes). Cell lines were 
accompanied by identification test certificates and were 
grown according to corresponding tissue culture 
collection protocols.  
 
Blood plasma of healthy human donors was obtained, as 
previously described [9], from buffy coat blood 
(purchased from healthy donors undergoing routine 
blood donation) which was bought from the National 
Health Blood and Transfusion Service (NHSBT, UK) 
following ethical approval (REC reference: 16-SS-033). 
Mononuclear-rich leukocytes were isolated using 
Ficoll-density centrifugation according to the 
manufacturer's protocol [9]. Cell numbers were 
determined using a haemocytometer and then diluted 
with HEPES-buffered Tyrode's solution before 
treatment as indicated. Primary human AML plasma 
samples and cells (cultured as described before) [32] 
were obtained from the sample bank of University 
Medical Centre Hamburg-Eppendorf (Ethik-
Kommission der Ärztekammer Hamburg, reference: 
PV3469).  
Primary human breast tumour tissue samples, together 
with paired corresponding peripheral non-transformed 
tissues of the same patients, were collected through 
surgery from breast cancer patients at the Colchester 
General Hospital, following informed written consent 
obtained before surgery [1]. Tissue specimens were 
visually examined by an experienced pathologist and 
fresh tumour tissues were selected using conventional 
pathologic criteria and further confirmed by subsequent 
histopathological examination. Normal (non-
transformed) peripheral tissues (also called “normal” or 
“healthy” tissues and abbreviated as HT in the figures) 
were selected at a distance from the site of the matching 
primary tumour; these tissues were microscopically 
inspected to confirm normal histology.  
 
Blood samples were collected before breast surgery 
from patients with primary breast cancer (PBC) and 
before treatment of patients who had metastatic breast 
cancer (MBC). Samples were also collected from 
healthy donors (individuals with no diagnosed 
pathology). Blood separation was performed using a 
buoyancy density method employing Histopaque 1119-
1 (Sigma, St. Louis, MO) according to the 
manufacturer's protocol [1]. Ethical approval for these 
studies was obtained from the NRES Essex Research 
Ethics Committee and the Research and Innovation 
Department of the Colchester Hospitals University, 
NHS Foundation Trust [MH 363 (AM03) and 
09/H0301/37]. 
 
Placental tissues (CVS, chorionic villus sampling) and 
amniotic fluids were collected after obtaining informed 
written consent from pregnant women at the University 
Hospital Bern. Cells were prepared and propagated as 
described before [33]. CVS was washed with PBS, 
treated with 270 U/ml of collagenase type 2 (Sigma, 
Buchs, Switzerland) for 50 min at 37° C, washed twice 
with PBS and cells were then re-suspended and cultured 
in CHANG medium (Irvine Scientific, Irvine, USA) 
according to the manufacturer’s instructions. Amniotic 
fluid samples were centrifuged and cell pellets were 
then re-suspended in CHANG medium. The first 
medium change was performed after 5 days of 
incubation at 37° C. The medium was then changed 
every second day until the number of cells was 
sufficient. 
 
Primary keratinocytes from cleft lip palate patients were 
cultured in keratinocyte medium as described 
previously [34]. Briefly, fresh tissue samples were 
placed into sterile tubes containing Dulbecco’s modified 
Eagles medium (DMEM, Gibco/Life Technologies; 
Thermo Fischer Scientific, Lucerne, Switzerland) 
supplemented with 10% FCS. The tissue was chopped 
into small pieces (< 1 mm
3
) and placed into 6-well 
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plates in 800 µl DMEM, 10% FCS, 1xAmphotericin B. 
In mixed cell-type outgrowths, fibroblasts were 
separated from keratinocytes by differential tryp-
sinization. Keratinocytes were then cultured in 
keratinocyte basal serum-free medium (KSFM, Gibco), 
supplemented with 25 mg/ml bovine pituitary extract, 
0.2 ng/ml epidermal growth factor, and CaCl2 to a final 
concentration of 0.4 mM, as previously described [35]. 
Primary cells were tested for their purity by qPCR and 
immunofluorescent staining [34]. Isolation of human 
cells was approved by the Kantonale Ethikkommission 
of Bern, Switzerland, protocol number 2017-01394). 
Written informed consent was obtained from the parents 
of the children involved. 
 
Plasmids 
 
Plasmid encoding hemagglutinin (HA)-tagged human 
ASK1 with kinase-dead domain (dominant-negative 
form), ΔN-ASK1, was a kind gift of Professor Ichijo 
(University of Tokyo, Tokyo, Japan). Plasmid was 
amplified using E. Coli XL10 Gold® (Stratagene 
Europe, Amsterdam, The Netherlands) and 
isolated/purified using the GenElute™ plasmid 
purification kit according to the manufacturer's 
protocol. Purified plasmids were transfected into THP-1 
cells using DOTAP transfection reagent according to 
the manufacturer's protocol [24]. 
 
Transfection of HIF-1α siRNA into MCF-7 cells 
 
siRNA specific to HIF-1α was selected as described 
previously and purchased from Sigma (Suffolk, UK) 
together with a mutated form of siRNA (called random 
siRNA, which was used as negative control) [24]. We 
employed a HIF-1α-specific siRNA target sequence 
(ugu gag uuc gca ucu uga u dtdt) localised at position 
146 bases downstream of the HIF-1α start codon. 
Smad3 siRNA was a commercially available reagent 
purchased from Ambion (ID 107876) through Thermo 
Fisher Scientific. Random (mutated) siRNA used as a 
negative control in all the knockdown experiments had 
the following sequence: uac acc guu agc aga cac c dtdt. 
siRNAs were transfected into THP-1 cells using 
DOTAP transfection reagent according to the 
manufacturer's protocol. Successful HIF-1α knockdown 
was verified by assessing HIF-1 DNA-binding activity. 
 
Western blot analysis 
 
Galectin-9, Tim-3, HIF-1α and phospho-S423/S425 
Smad-3 were measured by Western blot and compared to 
the amounts of β-actin (protein loading control), as 
previously described [1]. Cells were lysed in 50 mM Tris–
HCl, 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet-40, 1 
mM PMSF, pH 8.0. Tissue lysates for Western blot 
analysis were prepared as described previously. Briefly, 
100 mg of frozen tissues were grounded into a powder in 
dry ice, followed by the addition of 100 μl of tissue lysis 
buffer (20 mM Tris/HEPES pH 8.0, 2 mM EDTA, 0.5 M 
NaCl, 0.5% sodium deoxycholate, 0.5% Triton X-100, 
0.25 M sucrose, supplemented with 50 mM 2-
mercaptoethanol, 50 μM PMSF, and 1 μM pepstatin 
which was supplied just before use). Tissues were 
homogenised using a Polytron homogenizer (Capitol 
Scientific, USA) and a syringe was applied in order to 
acquire a homogenous tissue suspension. These tissue 
suspensions were then filtered through medical gauzes 
and centrifuged at +4° C at 10,000 g for 15 min. Proteins 
present in supernatants were precipitated by incubation of 
the samples on ice for 30 min with equal volumes of ice-
cold acetone. Protein pellets were obtained by 
centrifugation at +4° C, 10,000 g for 15 min followed by 
air drying at room temperature and then mixed with the 
SDS-lysis buffer described above. When measuring 
transcription factors, cell lysis buffer described above was 
also applied. 
 
Li-Cor goat secondary antibodies conjugated with 
infrared fluorescent dyes, were used as described in the 
manufacturer's protocol in order to visualise specific 
proteins (Li-Cor Odyssey imaging system was 
employed). Western blot data were quantitatively 
analysed using Odyssey software and values were 
subsequently normalised against those of β-actin or total 
protein loaded. 
 
Detection of HIF-1 DNA-binding activity 
 
HIF-1 DNA-binding activity was measured using the 
method similar to the one we recently described, with 
some modifications [36]. A 96-well Maxisorp™ 
microtitre plate was coated with streptavidin and blocked 
with BSA as described before. A volume of 2 pmol/well 
biotinylated 2HRE-containing oligonucleotide was 
immobilised by 1 h incubation at room temperature. The 
plate was then washed five times with TBST buffer (10 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20), 
followed by 1 h incubation with 20 μl/well of cell lysate at 
room temperature. The plate was again washed with 
TBST buffer and mouse anti-HIF-1α antibody (1:1 000 in 
TBS with 2% BSA) was added. After 1 h of incubation at 
room temperature the plate was washed with TBST buffer 
and then incubated with 1:1 000 Li-Cor goat anti-mouse 
secondary antibody labelled with infrared fluorescent dye. 
After extensive washing with TBST, the bound secondary 
antibody was detected using Li-Cor fluoroimager. 
 
Enzyme-linked immunosorbent assays (ELISAs) 
 
Secreted TGF-β, galectin-9 and Tim-3 were measured, 
either in cell culture medium or in blood plasma, by 
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ELISA using R&D Systems kits according to 
manufacturer’s protocols.  
 
Detection of xanthine oxidase and NADPH oxidase 
activities as well as quantitation of thiobarbiturate 
reactive species (TBRS) 
 
Xanthine oxidase activity was measured using a 
spectrophotometric assay described previously [21]. 
NADPH oxidase activity was measured based on the 
ability of this enzyme to produce superoxide anion 
radical [36]. TBRS were quantified using a previously 
described colorimetric assay [37]. 
 
Statistical analysis 
 
Each experiment was performed at least three times and 
statistical analysis, when comparing two normally 
distributed events at a time, was conducted using a two-
tailed Student's t-test. In cases when multiple 
comparisons (more than two groups) were performed, 
we used an ANOVA test. Post-hoc Bonferroni 
correction was used where applicable. Statistical 
probabilities (p) were expressed as * when p<0.05; **, 
p<0.01 and *** when p<0.001. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
 
 
Supplementary Figure 1. Values presented in Figure 1 normalised against total protein loaded for Western blot data and per 
1 mg of total tissue protein for enzyme activity and TBRS assays. Data are shown as mean values ± SEM of five independent 
experiments. * - p < 0.05 and ** - p < 0.01 vs non-transformed peripheral tissue abbreviated as HT (healthy tissue). 
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Supplementary Figure 2. TGF-β induces galectin-9 expression in K562 human cancer cells. K562 human chronic myeloid 
leukaemia cells were exposed for 24 h to 2, 4 or 8 ng/ml TGF-β followed by detection of phospho-S423/S425-Smad3 and galectin-9 
expression by Western blot. Galectin-9 release was analysed by ELISA. Images are from one experiment representative of three which gave 
similar results. Data are shown as mean values ± SEM of three independent experiments. 
